Advertisement

Current Psychiatry Reports

, 16:456 | Cite as

Natural Products and Supplements for Geriatric Depression and Cognitive Disorders: An Evaluation of the Research

  • Taya Varteresian
  • Helen Lavretsky
Geriatric Disorders (W McDonald, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Geriatric Disorders

Abstract

Numerous geriatric patients are using Complementary and Alternative Medicine (CAM) for late-life mood and cognitive disorders. Natural products and supplements are a common CAM intervention which have risks and benefits of which patients should be appropriately advised. The data for omega-3 fatty acids, ginkgo biloba, SAMe, St John’s wort, B vitamins and vitamin D, huperzine, caprylidene, and coconut oil will be evaluated. Since the evidence basis for natural products and supplements is limited, especially for the geriatric population, studies involving the general adult population are included to infer effects in the aging population. Despite the data available, more rigorous studies with larger sample sizes over longer periods of time are still needed. Regardless of a physician’s preference to recommend various natural supplements and products, a physician could protect their patients by having an understanding of the side effects and indications for various natural products.

Keywords

Natural products Supplements Geriatric Mood disorders Cognition Cognitive disorder Dementia Complementary and alternative medicine Integrative medicine Ginkgo biloba SAMe Omega-3 fatty acids St. John’s Wort Huperzine Vitamin D Vitamin B Caprylidene Coconut oil Folic acid Pyridoxine Cyanocobalamin 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Taya Varteresian declares no conflict of interest.

Helen Lavretsky declares that this work was supported by the NIH grants MH077650, MH86481 and AT003480, and grants from the Forest Research Institute, and Alzheimer’s Research and Prevention Foundation to Dr. Lavretsky.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lavretsky H et al. Complementary and alternative medicine use for treatment and prevention of late-life mood and cognitive disorders. Aging Health. 2009;5(1):61–78.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Lange H et al. Folate therapy in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Mozaffari-Khosravi H. The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency. J Clin Psychopharmacol. 2012;33(3):378–84.CrossRefGoogle Scholar
  4. 4.
    Michaelsson K et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92:841–8.PubMedCrossRefGoogle Scholar
  5. 5.
    NCCAM-NIH Website. What is Complementary and Alternative Medicine? http://nccam.nih.gov/health/whatiscam/. (National Center for Complementary and Alternative Medicine - National Institutes of Health, 2010).
  6. 6.
    Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States. Natl Health Stat Rep. 2007;2008:1–23.Google Scholar
  7. 7.
    US Food and Drug Administration. Orphan Drug Act (21 U.S.C. 360ee (b) (3)). Retrieved April 20, 2014, from http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/medicalfoods/default.htm (1988).
  8. 8.
    Bertrand PC, O’Kusky JR, Innis SM. Maternal dietary (n-3) fatty acid deficiency alters neurogenesis in the embryonic rat brain. J Nutr. 2006;136(6):1570–5.Google Scholar
  9. 9.
    Birch E et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351:1213.PubMedCrossRefGoogle Scholar
  11. 11.
    Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viinamaki H. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry. 2001;58:512–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord. 2004;82:447–52.PubMedGoogle Scholar
  13. 13.
    Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91:757–70.PubMedCrossRefGoogle Scholar
  14. 14.••
    Sublette ME, Steven PE, Gleant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72:1577–84. Summary of dosing and proportion of omega-3 fatty acids and depression in general adult population.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Rondanelli M, Giacosa A, Opizzi A, et al. Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J Nutr Health Aging. 2011;15:37–44.PubMedCrossRefGoogle Scholar
  16. 16.
    Giltay E, Geleijinse JM, Dromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr. 2011;94:1442–50.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407–12.PubMedCrossRefGoogle Scholar
  18. 18.••
    Sarris J, Dischoulon D, Schweitzer I. Omega-3 for bipolar disorder : meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81–6. Summary of omega-3 fatty acids and bipolar disorder in general adult population.PubMedCrossRefGoogle Scholar
  19. 19.
    Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol. 2009;5:140–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Schaefer EJ et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. Arch Neurol. 2006;63(11):1545–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Barberger-Gateau P et al. Dietary patterns and risk of dementia. Neurology. 2007;69:1921–30.PubMedCrossRefGoogle Scholar
  22. 22.••
    Mazereeuw G, et al. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol. Aging. 2012;1482.e17–1482.e29. Omega-3 fatty acids can be helpful in mild cognitive impairment but no AD or normal cognition. Google Scholar
  23. 23.••
    Sydenham E, et al. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012. Summary of 3 well –designed studies showing no support for omega-3 fatty acids preventing the development of AD Google Scholar
  24. 24.
    Trofimiuk E, Walesiuk A, Braszko JJ. St. John’s wort (Hypericum perforatum) diminishes cognitive impairment caused by chronic restraint stress in rats. Pharmacol Res. 2004;51:239–46.CrossRefGoogle Scholar
  25. 25.
    Hammerness P et al. St. John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44(4):271–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst. Rev. 2008;CD000448.Google Scholar
  27. 27.
    Kasper S, Gastpar M, Moller HJ, Muller WE, Volz HP, Dienel A, et al. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25:204–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. J Am Med Assoc. 2002;287:1807–14.CrossRefGoogle Scholar
  29. 29.
    Shelton RC. St John's wort (Hypericum perforatum) in major depression. J Clin Psychiatry. 2009;70 Suppl 5:23–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978–86.PubMedCrossRefGoogle Scholar
  31. 31.
    Sarris J, Fava M, Schweitzer I, Mischoulon D. St. John’s wort (hypericum perforatum) verses sertraline and placebo in major depressive disorder : continuation data from a 26-week RCT. Pharmacopsychiatry. 2012;45(7):275–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung. 1999;49:289–96.PubMedGoogle Scholar
  33. 33.
    Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H. St. John’s wort extract L160 for the treatment of depression with atypical features-a double-blind randomized, and placebo-controlled trial. J Psychiatr Res. 2001;44:760–7.CrossRefGoogle Scholar
  34. 34.
    Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69:1777–98.PubMedCrossRefGoogle Scholar
  35. 35.
    Kashiwaya Y et al. D-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. PNAS. 2000;97(5):5440–4.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Izzo AA et al. Interactions between herbal medicines and prescribed drugs an updated systematic reviews. Drugs. 2009;69(13):1888–98.CrossRefGoogle Scholar
  37. 37.••
    Thaipisuttikul P, Galvin J. Use of medical foods and nutritional approaches in treatment of Alzheimer’s disease. Clin Pract. 2012;9(2):199–209. Review of 3 popular medical foods for dementia.CrossRefGoogle Scholar
  38. 38.••
    Varteresian T et al. The use of natural products and supplements in late-life mood and cognitive disorders. FOCUS. 2013;11(1):15–21. Previous review of Natural products by current authors.CrossRefGoogle Scholar
  39. 39.
    Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76:1158S–61.PubMedGoogle Scholar
  40. 40.
    Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 5:18–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Paul RT, McDonnell AP, Kelly CB. Folic acid: neurochemistry, metabolism and relationship to depression. Hum Psychopharmacol. 2004;19:477–88.PubMedCrossRefGoogle Scholar
  42. 42.
    Bottiglieri T et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096–8.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7–14.PubMedCrossRefGoogle Scholar
  44. 44.
    Alpert JE et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder. J Clin Psychopharmacol. 2004;24(6):661–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167:942–8.PubMedCrossRefGoogle Scholar
  46. 46.
    DiRocco A et al. S-adenosyl-methionine improves mdepression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord. 2000;15(6):1225–9.CrossRefGoogle Scholar
  47. 47.
    Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76:1158S–61.PubMedGoogle Scholar
  48. 48.
    Carney MW, Chary TK, Bottiglieri T, Reynolds EH, Toone BK. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry J Ment Sci. 1987;150:724–5.CrossRefGoogle Scholar
  49. 49.
    Chitiva H, Audivert F, Alvarez C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine. J Nerv Ment Dis. 2012;200:99–101.PubMedCrossRefGoogle Scholar
  50. 50.
    Fontanari D, Palma C, Giorgetti G, Violante F, Voltolina M. Effects of S-adenosyl-L-methionin on cognitive and vigilance functions in the elderly. Curr Ther Res. 1994;55:682–8.CrossRefGoogle Scholar
  51. 51.•
    Levkovitz Y, Alpert J, Brintz C, Mischoulon D, Papakostas G. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2011;136:1174–8. RCT showing SAMe augmentation of SSRI benefiting cognitive symptoms in depression.Google Scholar
  52. 52.
    DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253–62.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Kohler S, Funk P, Kieser M. Influence of 7-day treatment with ginkgo biloba special extract Egb 761 on bleeding time and coagulation : a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis. 2004;15:303–9.PubMedCrossRefGoogle Scholar
  54. 54.••
    Vellas B et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11:851–9. Well designed study showing lack of preventatie effect of Ginkgo Biloba on the development of dementia.PubMedCrossRefGoogle Scholar
  55. 55.
    Snitz BE, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA. 2009; 2663–2670.Google Scholar
  56. 56.
    Amieva H et al. Ginkgo biloba extract and long-term cognitive decline : a 20-year follow-up population based study. PLoS ONE. 2013;8(1):e52755.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of a once daily formulation of ginkgo biloba extract EGb 761 i n Alzheimer’s Disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. 2012;45:41–6. RCT showing ginkgo biloba being effective for multiple types of dementia.PubMedCrossRefGoogle Scholar
  58. 58.
    Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157:295–300.PubMedCrossRefGoogle Scholar
  59. 59.
    Sierpina VS et al. Ginkgo biloba. Am Fam Physician. 2003;68(5):923–6.PubMedGoogle Scholar
  60. 60.•
    Zhi-Qiang X, Xiao-Min L, Juan W, Yuan-Feng Z, Chun-Xia Z, Xiao-Jiang J. Treatment with huperzine A improves cognition in vascular dementia patients. Cell Biochem Biophys. 2012;62:55–8. Study from China showing Huperzine being effective for vascular dementia.CrossRefGoogle Scholar
  61. 61.••
    Rafii MS et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76:1389–94. Study from U.S. showing only high dosage huperzine being effective for Alzheimer’s disease.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Beydoun M, Shroff M, Beydoun H, Zonderman A. Serum folate, vitamin B-12, and homocysteine and their associations with depressive symptoms among US adults. Psychosom Med. 2010;72:862–73.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Forti P, Rietti E, Pisacane N, Olivelli V, Dalmonte E, Mecocci P, et al. Blood homocysteine and risk of depression in the elderly. Arch Gerontol Geriatr. 2010;51:21–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan A, Breteler M. Vitamin B12, folate, and homocysteine in depression : the Rotterdam Study. Am J Psychiatr. 2002;159:2099–101.PubMedCrossRefGoogle Scholar
  65. 65.
    Walker J et al. Mental health literacy, folic acid and vitamin B12 and physical activity for the prevention of depression in older adults : randomized controlled trial. Br J Psychiatry. 2010;197:45–54.PubMedCrossRefGoogle Scholar
  66. 66.
    Almeida O, Marsh K, Alfonso H, Flicker L, Davis T, Hankey G. B-vitamins reduce the long-term risk of depression after stroke : the VITATOPS-DEP trial. Ann Neurol. 2010;68:503–10.PubMedCrossRefGoogle Scholar
  67. 67.••
    Papakostas GI et al. L-methyfolate as adjunctive therapy for SSRI-resistant major depression : results of two randomized, double blind, paralleel-sequential trials. Am J Psychiatry. 2012;169(12):1267–74. Well –designed study showing benefit of l-methyfolate augmentation of antidepressant in general adult population.PubMedCrossRefGoogle Scholar
  68. 68.
    Resler G, Lavie R, Campos J, Mata S, Urbina M, Garcia A, et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12 and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15:145–52.PubMedCrossRefGoogle Scholar
  69. 69.
    Abou-Saleh M, Coppen A. Folic acid and the treatment of depression. J Psychosom Res. 2006;61:285–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Seeley WW, Miller BL. Chapter 371. Dementia. In: Longo DL, Fauci, AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine, 18e. Retrieved September 17, 2012 from http://www.accessmedicine.com/content.aspx?aID=9146233 (2012).
  71. 71.
    Tangney CC et al. Vitamin B12, cognition, and brain MRI measures. Neurology. 2011;77:1276–82.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Aisen P, Schneider L, Sano M, Fiaz-Arrastia R, van-Dyck C, Weiner M, et al. High dose B vitamin supplementation and cognitive decline in Alzheimer Disease. JAMA. 2008;300:1774–83.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Kwok T et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr. 2011;30:297–302.PubMedCrossRefGoogle Scholar
  74. 74.•
    Walker J et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms-the Beyond Aging Project : a randomized controlled trial. Am J Clin Nutr. 2012;95:194–203. In older adults with depressive symptoms but without dementia showed vitamin B12 supplementation can improve attention and delayed recall.PubMedCrossRefGoogle Scholar
  75. 75.•
    Mursu J, Robien K, Harnack L, Park K, Jacobs D. Dietary supplements and mortality rate in older women. Arch Intern Med. 2011;171:1625–33. Epidemioliogical study showing some risk of supplements in increasing mortality in older women.PubMedCrossRefGoogle Scholar
  76. 76.•
    Tariq MM et al. Vitamin D : a potential role in reducing suicide risk. Int J Adolesc Med Health. 2011;23(3):157–65. Correlation between vitamin D deficiency and increased risk for suicide in general adult popultation.PubMedCrossRefGoogle Scholar
  77. 77.
    Dumville JC et al. Can vitamin D supplementation prevent winter-time blues ? a randomized trial among older women. J Nutr Health Aging. 2006;10(2):151–3.PubMedGoogle Scholar
  78. 78.
    Chan A, et al. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open label pilot study with a 16-month caregiver extension. Am J Alzheimers Dis Other Dement. 2009;571–585.Google Scholar
  79. 79.•
    Bertone-Johnson ER et al. Vitamin D supplementation and depression in the Women’s Health Initiative Calcium and Vitamin D Trial. Am J Epidemiol. 2011;176(1):1–13. Low dosage vitamin D supplementation did not improve depression in older females suffering from depression.CrossRefGoogle Scholar
  80. 80.
    Jorde R et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects : randomized double blind trial. J Intern Med. 2008;264:599–609.PubMedCrossRefGoogle Scholar
  81. 81.
    Henderson ST et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease : a randomized, double-blind placebo-controlled multicenter trial. Nutr Metab. 2009;6:31.CrossRefGoogle Scholar
  82. 82.•
    Doty L. Coconut oil for Alzheimer’s disease. Clin Pract. 2012;1(2):12–7. Review demonstrating how coconut oil is not effective for Alzheimer’s disease.Google Scholar
  83. 83.
    Stoll AL, Damico KE, Daly BP, Severus WE, Marangell LB. Methodological considerations in clinical studies of omega 3 fatty acids in major depression and bipolar disorder. World Rev Nutr Diet. 2001;88:58–67.PubMedCrossRefGoogle Scholar
  84. 84.
    Michaelsson K, Baron J, Snellman G, Gedborg R, Byberg L, Sundstrom J, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92:841–48.Google Scholar
  85. 85.••
    Qureshi NA et al. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat. 2013;9:639–58. Extensive review of CAM for adult mood disorders.PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Kaustubh JG, Faubion MD. Mania and psychosis associated with St. John’s wort and ginseng. Psychiatry. 2005;56–61.Google Scholar
  87. 87.
    Borrelli F, Izzo AA. Herb-drug interactions with St. John’s wort (Hypericum perforatum) an update on clinical observations. AAPS J. 2009;11:710–27.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human BehaviorDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.VA Long Beach Health Care SystemLong BeachUSA
  3. 3.University of California IrvineIrvineUSA

Personalised recommendations